1. Home
  2. LARK vs ADAG Comparison

LARK vs ADAG Comparison

Compare LARK & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Landmark Bancorp Inc.

LARK

Landmark Bancorp Inc.

N/A

Current Price

$26.68

Market Cap

161.7M

Sector

Finance

ML Signal

N/A

Logo Adagene Inc.

ADAG

Adagene Inc.

HOLD

Current Price

$3.82

Market Cap

254.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LARK
ADAG
Founded
1885
2011
Country
United States
China
Employees
283
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
161.7M
254.4M
IPO Year
2001
2020

Fundamental Metrics

Financial Performance
Metric
LARK
ADAG
Price
$26.68
$3.82
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$8.25
AVG Volume (30 Days)
3.2K
366.1K
Earning Date
04-29-2026
04-01-2026
Dividend Yield
3.07%
N/A
EPS Growth
35.84
N/A
EPS
3.07
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$8.69
N/A
Revenue Growth
N/A
N/A
52 Week Low
$23.43
$1.44
52 Week High
$30.85
$4.75

Technical Indicators

Market Signals
Indicator
LARK
ADAG
Relative Strength Index (RSI) 54.83 52.34
Support Level $27.01 $3.49
Resistance Level $28.93 $4.10
Average True Range (ATR) 0.64 0.23
MACD 0.01 -0.04
Stochastic Oscillator 45.69 67.44

Price Performance

Historical Comparison
LARK
ADAG

About LARK Landmark Bancorp Inc.

Landmark Bancorp Inc is the bank holding company for Landmark National Bank, which is dedicated to providing quality financial and banking services. The Bank has continued to focus on increasing its originations of commercial, commercial real estate (CRE), and agricultural loans, which management believes will be more profitable and provide more growth for the Bank than traditional one-to-four-family residential real estate lending. In addition, it also invests in certain investment and mortgage-related securities using deposits and other borrowings as funding sources. Its primary deposit gathering and lending markets are geographically diversified with locations in central, eastern, southeast, and Southwest Kansas.

About ADAG Adagene Inc.

Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.

Share on Social Networks: